NSCLC CRISPR therapy (Jenthera)

N/A

Report date: 2025/12/30 17:53:53

Base Information

Drug NameNSCLC CRISPR therapy (Jenthera)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing > CRISPR
Mechanisms of ActionKRAS G12D inhibitorsKRAS G12S inhibitors
TargetsKRAS G12DKRAS G12S
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJenthera Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesJenthera Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A